ATC Group: N06AX21 Duloxetine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06AX21 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06A Antidepressants
4 N06AX Other antidepressants
5 N06AX21 Duloxetine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 60 mg

Active ingredients in N06AX21

Active Ingredient Description
Duloxetine

Duloxetine is a combined serotonin (5-HT) and noradrenaline (NA) reuptake inhibitor. It weakly inhibits dopamine reuptake with no significant affinity for histaminergic, dopaminergic, cholinergic and adrenergic receptors.

Related product monographs

Title Information Source Document Type  
CYMBALTA Hard gastro-resistant capsule European Medicines Agency (EU) MPI, EU: SmPC
LOXENTIA Hard gastro-resistant capsule Health Products Regulatory Authority (IE) MPI, EU: SmPC
YENTREVE Hard gastro-resistant capsule European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Canada (CA)

Cyprus (CY)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Malta (MT)

Mexico (MX)

Netherlands (NL)

Singapore (SG)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.